Indeed, the Hsp90/Cdc37 inhibitors celastrol, (−)-epigallocatechin-3-gallate (EGCG, identified also in this study), and withaferin A were previously successfully tested against pancreatic cancer cell growth in vitro and in vivo by the Sun group [22,24,53]. Here, HSP90AB1 is linked to pancreatic neoplasm.